nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—CYP2D6—Hydroxyurea—head and neck cancer	0.244	0.289	CbGbCtD
Loratadine—CYP2C8—Fluorouracil—head and neck cancer	0.146	0.173	CbGbCtD
Loratadine—CYP2C9—Fluorouracil—head and neck cancer	0.102	0.121	CbGbCtD
Loratadine—ABCB1—Vinblastine—head and neck cancer	0.0918	0.108	CbGbCtD
Loratadine—CYP2D6—Vinblastine—head and neck cancer	0.0865	0.102	CbGbCtD
Loratadine—ABCB1—Docetaxel—head and neck cancer	0.0757	0.0893	CbGbCtD
Loratadine—CYP3A4—Vinblastine—head and neck cancer	0.055	0.0649	CbGbCtD
Loratadine—CYP3A4—Docetaxel—head and neck cancer	0.0453	0.0535	CbGbCtD
Loratadine—Blister—Hydroxyurea—head and neck cancer	0.0056	0.0399	CcSEcCtD
Loratadine—Blister—Fluorouracil—head and neck cancer	0.00403	0.0287	CcSEcCtD
Loratadine—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00306	0.0219	CcSEcCtD
Loratadine—Depression—Vinblastine—head and neck cancer	0.00247	0.0176	CcSEcCtD
Loratadine—Drug interaction—Docetaxel—head and neck cancer	0.00226	0.0161	CcSEcCtD
Loratadine—Drowsiness—Hydroxyurea—head and neck cancer	0.00226	0.0161	CcSEcCtD
Loratadine—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00221	0.0157	CcSEcCtD
Loratadine—Pharyngitis—Vinblastine—head and neck cancer	0.00221	0.0157	CcSEcCtD
Loratadine—Lethargy—Fluorouracil—head and neck cancer	0.00215	0.0153	CcSEcCtD
Loratadine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00213	0.0152	CcSEcCtD
Loratadine—Alopecia—Vinblastine—head and neck cancer	0.00196	0.014	CcSEcCtD
Loratadine—Ill-defined disorder—Vinblastine—head and neck cancer	0.00179	0.0128	CcSEcCtD
Loratadine—Alopecia—Hydroxyurea—head and neck cancer	0.00179	0.0128	CcSEcCtD
Loratadine—Malaise—Vinblastine—head and neck cancer	0.00174	0.0124	CcSEcCtD
Loratadine—Hypertension—Vinblastine—head and neck cancer	0.00167	0.0119	CcSEcCtD
Loratadine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00164	0.0117	CcSEcCtD
Loratadine—Discomfort—Vinblastine—head and neck cancer	0.00163	0.0116	CcSEcCtD
Loratadine—Dermatitis bullous—Docetaxel—head and neck cancer	0.00159	0.0114	CcSEcCtD
Loratadine—Malaise—Hydroxyurea—head and neck cancer	0.00159	0.0113	CcSEcCtD
Loratadine—Lethargy—Docetaxel—head and neck cancer	0.00155	0.0111	CcSEcCtD
Loratadine—Epistaxis—Fluorouracil—head and neck cancer	0.00153	0.0109	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00149	0.0106	CcSEcCtD
Loratadine—Discomfort—Hydroxyurea—head and neck cancer	0.00148	0.0106	CcSEcCtD
Loratadine—Pharyngitis—Fluorouracil—head and neck cancer	0.00145	0.0103	CcSEcCtD
Loratadine—Paraesthesia—Vinblastine—head and neck cancer	0.00142	0.0101	CcSEcCtD
Loratadine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00141	0.0101	CcSEcCtD
Loratadine—Skin disorder—Hydroxyurea—head and neck cancer	0.0014	0.00998	CcSEcCtD
Loratadine—Abdominal pain upper—Docetaxel—head and neck cancer	0.00139	0.00991	CcSEcCtD
Loratadine—Pain—Vinblastine—head and neck cancer	0.00135	0.00963	CcSEcCtD
Loratadine—Constipation—Vinblastine—head and neck cancer	0.00135	0.00963	CcSEcCtD
Loratadine—Arrhythmia—Fluorouracil—head and neck cancer	0.0013	0.0093	CcSEcCtD
Loratadine—Feeling abnormal—Vinblastine—head and neck cancer	0.0013	0.00928	CcSEcCtD
Loratadine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00129	0.00921	CcSEcCtD
Loratadine—Alopecia—Fluorouracil—head and neck cancer	0.00129	0.00919	CcSEcCtD
Loratadine—Somnolence—Hydroxyurea—head and neck cancer	0.00128	0.00913	CcSEcCtD
Loratadine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00127	0.00904	CcSEcCtD
Loratadine—Abdominal pain—Vinblastine—head and neck cancer	0.00125	0.0089	CcSEcCtD
Loratadine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00124	0.00887	CcSEcCtD
Loratadine—Fatigue—Hydroxyurea—head and neck cancer	0.00124	0.00885	CcSEcCtD
Loratadine—Pain—Hydroxyurea—head and neck cancer	0.00123	0.00878	CcSEcCtD
Loratadine—Constipation—Hydroxyurea—head and neck cancer	0.00123	0.00878	CcSEcCtD
Loratadine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00119	0.00846	CcSEcCtD
Loratadine—Body temperature increased—Hydroxyurea—head and neck cancer	0.00114	0.00812	CcSEcCtD
Loratadine—Asthenia—Vinblastine—head and neck cancer	0.00113	0.00808	CcSEcCtD
Loratadine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00111	0.00791	CcSEcCtD
Loratadine—Epistaxis—Docetaxel—head and neck cancer	0.00111	0.00789	CcSEcCtD
Loratadine—Chest pain—Fluorouracil—head and neck cancer	0.00108	0.00771	CcSEcCtD
Loratadine—Myalgia—Fluorouracil—head and neck cancer	0.00108	0.00771	CcSEcCtD
Loratadine—Diarrhoea—Vinblastine—head and neck cancer	0.00108	0.00771	CcSEcCtD
Loratadine—Discomfort—Fluorouracil—head and neck cancer	0.00107	0.00762	CcSEcCtD
Loratadine—Pharyngitis—Docetaxel—head and neck cancer	0.00104	0.00745	CcSEcCtD
Loratadine—Dizziness—Vinblastine—head and neck cancer	0.00104	0.00745	CcSEcCtD
Loratadine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00104	0.00739	CcSEcCtD
Loratadine—Asthenia—Hydroxyurea—head and neck cancer	0.00103	0.00737	CcSEcCtD
Loratadine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00102	0.00725	CcSEcCtD
Loratadine—Tachycardia—Fluorouracil—head and neck cancer	0.00101	0.00721	CcSEcCtD
Loratadine—Vomiting—Vinblastine—head and neck cancer	0.001	0.00716	CcSEcCtD
Loratadine—Headache—Vinblastine—head and neck cancer	0.000989	0.00705	CcSEcCtD
Loratadine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000985	0.00703	CcSEcCtD
Loratadine—Hypotension—Fluorouracil—head and neck cancer	0.000968	0.00691	CcSEcCtD
Loratadine—Dizziness—Hydroxyurea—head and neck cancer	0.000952	0.00679	CcSEcCtD
Loratadine—Immune system disorder—Docetaxel—head and neck cancer	0.000951	0.00678	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000944	0.00673	CcSEcCtD
Loratadine—Arrhythmia—Docetaxel—head and neck cancer	0.000941	0.00671	CcSEcCtD
Loratadine—Nausea—Vinblastine—head and neck cancer	0.000938	0.00669	CcSEcCtD
Loratadine—Insomnia—Fluorouracil—head and neck cancer	0.000937	0.00669	CcSEcCtD
Loratadine—Paraesthesia—Fluorouracil—head and neck cancer	0.000931	0.00664	CcSEcCtD
Loratadine—Alopecia—Docetaxel—head and neck cancer	0.00093	0.00664	CcSEcCtD
Loratadine—Somnolence—Fluorouracil—head and neck cancer	0.000921	0.00657	CcSEcCtD
Loratadine—Vomiting—Hydroxyurea—head and neck cancer	0.000915	0.00653	CcSEcCtD
Loratadine—Dyspepsia—Fluorouracil—head and neck cancer	0.000912	0.00651	CcSEcCtD
Loratadine—Rash—Hydroxyurea—head and neck cancer	0.000908	0.00648	CcSEcCtD
Loratadine—Dermatitis—Hydroxyurea—head and neck cancer	0.000907	0.00647	CcSEcCtD
Loratadine—Headache—Hydroxyurea—head and neck cancer	0.000902	0.00643	CcSEcCtD
Loratadine—Dysgeusia—Docetaxel—head and neck cancer	0.000897	0.0064	CcSEcCtD
Loratadine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000895	0.00638	CcSEcCtD
Loratadine—Pain—Fluorouracil—head and neck cancer	0.000886	0.00632	CcSEcCtD
Loratadine—Nausea—Hydroxyurea—head and neck cancer	0.000855	0.0061	CcSEcCtD
Loratadine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000854	0.00609	CcSEcCtD
Loratadine—Syncope—Docetaxel—head and neck cancer	0.000822	0.00586	CcSEcCtD
Loratadine—Body temperature increased—Fluorouracil—head and neck cancer	0.000819	0.00584	CcSEcCtD
Loratadine—Palpitations—Docetaxel—head and neck cancer	0.00081	0.00578	CcSEcCtD
Loratadine—Loss of consciousness—Docetaxel—head and neck cancer	0.000806	0.00575	CcSEcCtD
Loratadine—Cough—Docetaxel—head and neck cancer	0.0008	0.0057	CcSEcCtD
Loratadine—Hypertension—Docetaxel—head and neck cancer	0.000791	0.00564	CcSEcCtD
Loratadine—Chest pain—Docetaxel—head and neck cancer	0.00078	0.00557	CcSEcCtD
Loratadine—Myalgia—Docetaxel—head and neck cancer	0.00078	0.00557	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000775	0.00553	CcSEcCtD
Loratadine—Dry mouth—Docetaxel—head and neck cancer	0.000763	0.00544	CcSEcCtD
Loratadine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000748	0.00534	CcSEcCtD
Loratadine—Shock—Docetaxel—head and neck cancer	0.000736	0.00525	CcSEcCtD
Loratadine—Nervous system disorder—Docetaxel—head and neck cancer	0.000734	0.00523	CcSEcCtD
Loratadine—Tachycardia—Docetaxel—head and neck cancer	0.00073	0.00521	CcSEcCtD
Loratadine—Skin disorder—Docetaxel—head and neck cancer	0.000727	0.00518	CcSEcCtD
Loratadine—KCNH2—Hematopoietic Stem Cell Differentiation—CSF3—head and neck cancer	0.000714	0.0569	CbGpPWpGaD
Loratadine—Diarrhoea—Fluorouracil—head and neck cancer	0.000709	0.00506	CcSEcCtD
Loratadine—Hypotension—Docetaxel—head and neck cancer	0.000699	0.00499	CcSEcCtD
Loratadine—Dizziness—Fluorouracil—head and neck cancer	0.000685	0.00489	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000681	0.00486	CcSEcCtD
Loratadine—Insomnia—Docetaxel—head and neck cancer	0.000677	0.00483	CcSEcCtD
Loratadine—Paraesthesia—Docetaxel—head and neck cancer	0.000672	0.00479	CcSEcCtD
Loratadine—Somnolence—Docetaxel—head and neck cancer	0.000665	0.00474	CcSEcCtD
Loratadine—Vomiting—Fluorouracil—head and neck cancer	0.000659	0.0047	CcSEcCtD
Loratadine—Dyspepsia—Docetaxel—head and neck cancer	0.000658	0.0047	CcSEcCtD
Loratadine—Rash—Fluorouracil—head and neck cancer	0.000653	0.00466	CcSEcCtD
Loratadine—Dermatitis—Fluorouracil—head and neck cancer	0.000653	0.00466	CcSEcCtD
Loratadine—Headache—Fluorouracil—head and neck cancer	0.000649	0.00463	CcSEcCtD
Loratadine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000646	0.00461	CcSEcCtD
Loratadine—Fatigue—Docetaxel—head and neck cancer	0.000645	0.0046	CcSEcCtD
Loratadine—Pain—Docetaxel—head and neck cancer	0.00064	0.00456	CcSEcCtD
Loratadine—Constipation—Docetaxel—head and neck cancer	0.00064	0.00456	CcSEcCtD
Loratadine—Feeling abnormal—Docetaxel—head and neck cancer	0.000616	0.0044	CcSEcCtD
Loratadine—Nausea—Fluorouracil—head and neck cancer	0.000616	0.00439	CcSEcCtD
Loratadine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000612	0.00436	CcSEcCtD
Loratadine—Abdominal pain—Docetaxel—head and neck cancer	0.000591	0.00422	CcSEcCtD
Loratadine—Body temperature increased—Docetaxel—head and neck cancer	0.000591	0.00422	CcSEcCtD
Loratadine—Asthenia—Docetaxel—head and neck cancer	0.000537	0.00383	CcSEcCtD
Loratadine—Diarrhoea—Docetaxel—head and neck cancer	0.000512	0.00365	CcSEcCtD
Loratadine—Dizziness—Docetaxel—head and neck cancer	0.000495	0.00353	CcSEcCtD
Loratadine—Vomiting—Docetaxel—head and neck cancer	0.000476	0.00339	CcSEcCtD
Loratadine—Rash—Docetaxel—head and neck cancer	0.000472	0.00336	CcSEcCtD
Loratadine—Dermatitis—Docetaxel—head and neck cancer	0.000471	0.00336	CcSEcCtD
Loratadine—Headache—Docetaxel—head and neck cancer	0.000469	0.00334	CcSEcCtD
Loratadine—Nausea—Docetaxel—head and neck cancer	0.000444	0.00317	CcSEcCtD
Loratadine—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000416	0.0332	CbGpPWpGaD
Loratadine—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000379	0.0302	CbGpPWpGaD
Loratadine—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000372	0.0296	CbGpPWpGaD
Loratadine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000339	0.027	CbGpPWpGaD
Loratadine—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000338	0.0269	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—CEBPA—head and neck cancer	0.000314	0.025	CbGpPWpGaD
Loratadine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000308	0.0246	CbGpPWpGaD
Loratadine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.000262	0.0209	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—STAT6—head and neck cancer	0.000251	0.02	CbGpPWpGaD
Loratadine—KCNH2—Hematopoietic Stem Cell Differentiation—NOTCH1—head and neck cancer	0.000235	0.0187	CbGpPWpGaD
Loratadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000223	0.0177	CbGpPWpGaD
Loratadine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000208	0.0166	CbGpPWpGaD
Loratadine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.000203	0.0162	CbGpPWpGaD
Loratadine—CYP2C8—Xenobiotics—CYP1A1—head and neck cancer	0.0002	0.0159	CbGpPWpGaD
Loratadine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000196	0.0156	CbGpPWpGaD
Loratadine—CYP2C8—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000192	0.0153	CbGpPWpGaD
Loratadine—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	0.000179	0.0142	CbGpPWpGaD
Loratadine—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000172	0.0137	CbGpPWpGaD
Loratadine—CYP2D6—Xenobiotics—CYP1A1—head and neck cancer	0.000164	0.0131	CbGpPWpGaD
Loratadine—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.000163	0.013	CbGpPWpGaD
Loratadine—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000158	0.0126	CbGpPWpGaD
Loratadine—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000157	0.0125	CbGpPWpGaD
Loratadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000137	0.0109	CbGpPWpGaD
Loratadine—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000133	0.0106	CbGpPWpGaD
Loratadine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000128	0.0102	CbGpPWpGaD
Loratadine—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000123	0.00982	CbGpPWpGaD
Loratadine—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000122	0.00972	CbGpPWpGaD
Loratadine—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.000117	0.00931	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—KISS1—head and neck cancer	0.000116	0.00925	CbGpPWpGaD
Loratadine—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000107	0.00855	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.000104	0.00828	CbGpPWpGaD
Loratadine—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000103	0.00823	CbGpPWpGaD
Loratadine—CYP2C8—Arachidonic acid metabolism—GPX1—head and neck cancer	9.71e-05	0.00774	CbGpPWpGaD
Loratadine—CYP2C8—Arachidonic acid metabolism—CYP1A1—head and neck cancer	9.61e-05	0.00766	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—GRP—head and neck cancer	9.56e-05	0.00762	CbGpPWpGaD
Loratadine—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	8.67e-05	0.0069	CbGpPWpGaD
Loratadine—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	8.58e-05	0.00684	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	8.55e-05	0.00681	CbGpPWpGaD
Loratadine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	8.31e-05	0.00662	CbGpPWpGaD
Loratadine—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	8.2e-05	0.00653	CbGpPWpGaD
Loratadine—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	7.9e-05	0.0063	CbGpPWpGaD
Loratadine—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	7.82e-05	0.00623	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	7.69e-05	0.00613	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—NAT2—head and neck cancer	7.64e-05	0.00609	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—NAT2—head and neck cancer	7.53e-05	0.006	CbGpPWpGaD
Loratadine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	7.41e-05	0.00591	CbGpPWpGaD
Loratadine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	7.32e-05	0.00583	CbGpPWpGaD
Loratadine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	6.82e-05	0.00543	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—NAT2—head and neck cancer	6.82e-05	0.00543	CbGpPWpGaD
Loratadine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	6.76e-05	0.00539	CbGpPWpGaD
Loratadine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.73e-05	0.00537	CbGpPWpGaD
Loratadine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	6.73e-05	0.00536	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	6.73e-05	0.00536	CbGpPWpGaD
Loratadine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	6.67e-05	0.00532	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	6.33e-05	0.00505	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—NAT2—head and neck cancer	6.27e-05	0.005	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—NAT2—head and neck cancer	6.22e-05	0.00495	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	6.19e-05	0.00493	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	6.13e-05	0.00489	CbGpPWpGaD
Loratadine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.01e-05	0.00479	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—KISS1—head and neck cancer	5.86e-05	0.00467	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—STAT3—head and neck cancer	5.79e-05	0.00461	CbGpPWpGaD
Loratadine—CYP2C8—Arachidonic acid metabolism—PTGS2—head and neck cancer	5.72e-05	0.00455	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	5.6e-05	0.00446	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—MAPK3—head and neck cancer	5.53e-05	0.00441	CbGpPWpGaD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	5.53e-05	0.0044	CbGpPWpGaD
Loratadine—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	5.51e-05	0.00439	CbGpPWpGaD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	5.48e-05	0.00437	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—MAPK1—head and neck cancer	5.26e-05	0.0042	CbGpPWpGaD
Loratadine—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	5.1e-05	0.00406	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	5.09e-05	0.00406	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—GRP—head and neck cancer	4.82e-05	0.00384	CbGpPWpGaD
Loratadine—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	4.65e-05	0.00371	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	4.63e-05	0.00369	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—PIK3CA—head and neck cancer	4.57e-05	0.00364	CbGpPWpGaD
Loratadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	4.46e-05	0.00355	CbGpPWpGaD
Loratadine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	4.4e-05	0.00351	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CASP8—head and neck cancer	4.24e-05	0.00338	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—NAT2—head and neck cancer	4.1e-05	0.00327	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	4.04e-05	0.00322	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—GSTM1—head and neck cancer	3.77e-05	0.00301	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—AKT1—head and neck cancer	3.73e-05	0.00297	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—GSTM1—head and neck cancer	3.72e-05	0.00297	CbGpPWpGaD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	3.61e-05	0.00288	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—CYP1A1—head and neck cancer	3.58e-05	0.00285	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—CYP1A1—head and neck cancer	3.53e-05	0.00281	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	3.37e-05	0.00268	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	3.32e-05	0.00265	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—KISS1—head and neck cancer	3.31e-05	0.00264	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL2—head and neck cancer	3.2e-05	0.00255	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	3.19e-05	0.00254	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	3.15e-05	0.00251	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—UROD—head and neck cancer	3.15e-05	0.00251	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	3.14e-05	0.0025	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	3.1e-05	0.00247	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	3.07e-05	0.00245	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	3.07e-05	0.00245	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	3.06e-05	0.00244	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	3.05e-05	0.00243	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	3.03e-05	0.00241	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—KISS1—head and neck cancer	3.01e-05	0.00239	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	2.94e-05	0.00234	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	2.91e-05	0.00232	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	2.9e-05	0.00231	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	2.87e-05	0.00229	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—UROD—head and neck cancer	2.81e-05	0.00224	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—UROD—head and neck cancer	2.74e-05	0.00218	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—GRP—head and neck cancer	2.73e-05	0.00217	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	2.72e-05	0.00217	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—MAPK1—head and neck cancer	2.62e-05	0.00209	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—UROD—head and neck cancer	2.58e-05	0.00206	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—UROD—head and neck cancer	2.56e-05	0.00204	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—GRP—head and neck cancer	2.47e-05	0.00197	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.44e-05	0.00194	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.18e-05	0.00174	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—HRAS—head and neck cancer	2.1e-05	0.00167	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	2.09e-05	0.00167	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	2.03e-05	0.00161	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	2e-05	0.0016	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	2e-05	0.00159	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	1.99e-05	0.00158	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	1.92e-05	0.00153	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	1.89e-05	0.00151	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	1.83e-05	0.00146	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	1.79e-05	0.00143	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—KISS1—head and neck cancer	1.78e-05	0.00141	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	1.74e-05	0.00139	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	1.74e-05	0.00139	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	1.7e-05	0.00136	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—PIK3CA—head and neck cancer	1.69e-05	0.00135	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—UROD—head and neck cancer	1.69e-05	0.00135	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	1.54e-05	0.00123	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	1.51e-05	0.00121	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	1.49e-05	0.00118	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—GRP—head and neck cancer	1.46e-05	0.00116	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—STAT6—head and neck cancer	1.42e-05	0.00113	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	1.4e-05	0.00112	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.39e-05	0.00111	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.37e-05	0.00109	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	1.34e-05	0.00107	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NAT2—head and neck cancer	1.31e-05	0.00104	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	1.27e-05	0.00101	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—YAP1—head and neck cancer	1.26e-05	0.001	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.24e-05	0.000987	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.23e-05	0.000977	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	1.21e-05	0.000963	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	1.21e-05	0.000963	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NAT2—head and neck cancer	1.17e-05	0.000929	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—DPYD—head and neck cancer	1.15e-05	0.000913	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NAT2—head and neck cancer	1.14e-05	0.000907	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.13e-05	0.0009	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.12e-05	0.000891	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—YAP1—head and neck cancer	1.09e-05	0.000866	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NAT2—head and neck cancer	1.07e-05	0.000855	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NAT2—head and neck cancer	1.06e-05	0.000847	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	1.05e-05	0.000835	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—DPYD—head and neck cancer	1.02e-05	0.000815	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	1.01e-05	0.000808	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—DPYD—head and neck cancer	9.98e-06	0.000795	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—YAP1—head and neck cancer	9.7e-06	0.000773	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—YAP1—head and neck cancer	9.47e-06	0.000755	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—DPYD—head and neck cancer	9.4e-06	0.000749	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—DPYD—head and neck cancer	9.32e-06	0.000743	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—YAP1—head and neck cancer	8.92e-06	0.000711	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—YAP1—head and neck cancer	8.85e-06	0.000705	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	8.56e-06	0.000682	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.17e-06	0.000651	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.29e-06	0.000581	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—IL2—head and neck cancer	7.26e-06	0.000579	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.12e-06	0.000568	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NAT2—head and neck cancer	7.01e-06	0.000559	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.65e-06	0.00053	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL2—head and neck cancer	6.59e-06	0.000525	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—TYMS—head and neck cancer	6.53e-06	0.00052	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTM1—head and neck cancer	6.45e-06	0.000514	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.36e-06	0.000507	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GPX1—head and neck cancer	6.18e-06	0.000492	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—DPYD—head and neck cancer	6.15e-06	0.00049	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP1A1—head and neck cancer	6.12e-06	0.000487	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—YAP1—head and neck cancer	5.83e-06	0.000465	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—TYMS—head and neck cancer	5.83e-06	0.000464	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.8e-06	0.000462	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTM1—head and neck cancer	5.76e-06	0.000459	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—TYMS—head and neck cancer	5.69e-06	0.000453	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—NOTCH1—head and neck cancer	5.66e-06	0.000451	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTM1—head and neck cancer	5.62e-06	0.000448	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GPX1—head and neck cancer	5.52e-06	0.000439	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP1A1—head and neck cancer	5.46e-06	0.000435	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GPX1—head and neck cancer	5.38e-06	0.000429	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—TYMS—head and neck cancer	5.36e-06	0.000427	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP1A1—head and neck cancer	5.33e-06	0.000425	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—TYMS—head and neck cancer	5.31e-06	0.000423	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—MAPK3—head and neck cancer	5.3e-06	0.000422	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTM1—head and neck cancer	5.3e-06	0.000422	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTM1—head and neck cancer	5.25e-06	0.000418	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GPX1—head and neck cancer	5.07e-06	0.000404	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—MAPK1—head and neck cancer	5.04e-06	0.000402	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—EGFR—head and neck cancer	5.04e-06	0.000402	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GPX1—head and neck cancer	5.03e-06	0.000401	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.03e-06	0.0004	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.02e-06	0.0004	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	4.98e-06	0.000397	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—PIK3CA—head and neck cancer	4.82e-06	0.000384	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.49e-06	0.000357	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	4.38e-06	0.000349	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.09e-06	0.000326	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HRAS—head and neck cancer	4.05e-06	0.000323	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	3.94e-06	0.000314	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL2—head and neck cancer	3.9e-06	0.00031	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCND1—head and neck cancer	3.8e-06	0.000303	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PTEN—head and neck cancer	3.67e-06	0.000292	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PTGS2—head and neck cancer	3.64e-06	0.00029	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—AKT1—head and neck cancer	3.58e-06	0.000285	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—TYMS—head and neck cancer	3.5e-06	0.000279	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.46e-06	0.000276	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GPX1—head and neck cancer	3.32e-06	0.000264	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—VEGFA—head and neck cancer	3.31e-06	0.000264	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.28e-06	0.000262	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—STAT3—head and neck cancer	3.28e-06	0.000261	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PTGS2—head and neck cancer	3.25e-06	0.000259	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PTEN—head and neck cancer	3.17e-06	0.000253	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PTGS2—head and neck cancer	3.17e-06	0.000253	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MAPK3—head and neck cancer	3.13e-06	0.00025	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PTGS2—head and neck cancer	2.99e-06	0.000238	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MAPK1—head and neck cancer	2.98e-06	0.000237	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EGFR—head and neck cancer	2.98e-06	0.000237	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PTGS2—head and neck cancer	2.96e-06	0.000236	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PTEN—head and neck cancer	2.83e-06	0.000226	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PTEN—head and neck cancer	2.76e-06	0.00022	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PTEN—head and neck cancer	2.6e-06	0.000208	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	2.59e-06	0.000206	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PTEN—head and neck cancer	2.58e-06	0.000206	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TP53—head and neck cancer	2.5e-06	0.000199	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HRAS—head and neck cancer	2.39e-06	0.000191	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PIK3CA—head and neck cancer	2.24e-06	0.000178	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—AKT1—head and neck cancer	2.11e-06	0.000168	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	2e-06	0.000159	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.95e-06	0.000156	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.95e-06	0.000155	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.84e-06	0.000146	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—AKT1—head and neck cancer	1.83e-06	0.000146	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	1.82e-06	0.000145	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PTEN—head and neck cancer	1.7e-06	0.000136	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—AKT1—head and neck cancer	1.63e-06	0.00013	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—AKT1—head and neck cancer	1.59e-06	0.000127	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—AKT1—head and neck cancer	1.5e-06	0.00012	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—AKT1—head and neck cancer	1.49e-06	0.000119	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.2e-06	9.57e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—AKT1—head and neck cancer	9.81e-07	7.82e-05	CbGpPWpGaD
